8-K: Tenax Therapeutics Pauses Trial Enrollment for Strategic Refinement

Tenax Therapeutics is temporarily pausing enrollment in its LEVEL-2 clinical trial to amend patient selection criteria based on learnings from the LEVEL Phase 3 trial, aiming to enrich the study population for better efficacy outcomes.

Summary

• Tenax Therapeutics is updating its LEVEL-2 clinical trial for TNX-103 (oral levosimendan) in PH-HFpEF.
• Enrollment in LEVEL-2 has been temporarily paused to amend the protocol.
• The amendment is based on key learnings from the Phase 3 LEVEL trial, which did not meet its primary endpoint of 6-minute walk distance (6MWD) in the overall population.
• Analysis of the LEVEL trial data indicates a strong treatment effect in specific patient subgroups, particularly those with lower baseline 6MWD (<333 meters) or specific combinations of 6MWD and Right Atrial Volume Index (RAVI).
• The company has requested a Type C meeting with the FDA to discuss the development of levosimendan.
• An updated investor presentation detailing these changes is attached to the filing.
• The company expects to be funded through Q2 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic development. While the primary endpoint of the LEVEL trial was missed, the company has identified a specific patient subgroup that showed significant benefit, leading to a strategic pivot for the ongoing LEVEL-2 trial. This suggests a path forward but introduces uncertainty regarding the revised trial's success.

Positives

• The LEVEL trial data suggests a clear patient enrichment strategy for the LEVEL-2 trial, focusing on patients most likely to benefit from oral levosimendan.
• A strong treatment effect was observed in patients with a baseline 6MWD below 333 meters (+26.3 M improvement vs. placebo, p=0.0112).
• NT-proBNP was reduced by 49% in the overall population (p < 0.0001), indicating a biological effect.
• Right Ventricular Systolic Pressure (RVSP) was reduced by 4.9 mmHg in patients with baseline 6MWD below the median.
• Oral levosimendan (TNX-103) has a well-established safety profile.
• The company believes the LEVEL trial confirmed the biological thesis and explained the primary endpoint miss due to patient selection, not drug efficacy.
• The company is funded through Q2 2028.

Negatives

• The Phase 3 LEVEL trial did not meet its primary endpoint of change in 6-minute walk distance (6MWD) in the overall enrolled population.
• Enrollment in the LEVEL-2 trial has been temporarily paused.
• Treatment-emergent adverse events were higher in the TNX-103 arm (86.7%) compared to placebo (71.9%), with a higher rate leading to treatment discontinuation (8.3% vs 1.7%).
• Treatment-related adverse events were also higher in the TNX-103 arm (38.3% vs 17.4%).
• The company's interpretation of the LEVEL trial data may not be shared by regulatory authorities or the scientific community.

Risks

• The risk that the company's interpretation and characterization of clinical trial data may not be shared by regulatory authorities, the medical and scientific communities, or investors.
• The risk that data from the LEVEL trial that the company views as supportive of its LEVEL-2 trial design might not be predictive of LEVEL-2 outcomes.
• Any delays in regulatory review and approval of product candidates in development.
• Risks related to the business strategy, including the prioritization and development of product candidates.
• Reliance on third parties, including manufacturers and CROs.
• Risks regarding the formulation, production, marketing, customer acceptance, and clinical utility of product candidates.
• Volatility and uncertainty in the global economy and financial markets.
• Risks associated with the company's cash needs.

Future Outlook

The company is amending the LEVEL-2 trial protocol to enrich the patient population based on learnings from the LEVEL trial, focusing on patients with higher disease burden who demonstrated a stronger treatment effect. This strategic adjustment aims to increase the likelihood of a positive outcome in the ongoing Phase 3 trial. Further updates on levosimendan development are expected in Q1 2027.

Management Comments

• "The Company intends to amend LEVEL-2 enrollment criteria, as set forth in the attached Investor Presentation."
• "To maximize the enrollment of these patients, whom LEVEL results suggest are those most likely to demonstrate improved exercise tolerance in the primary endpoint of LEVEL-2, the Company has temporarily paused enrollment in LEVEL-2."
• "The Company has requested a Type C meeting with the U.S. Food and Drug Administration to discuss the overall development of levosimendan."
• "LEVEL data validates levosimendan MOA in PH-HFpEF and defines clear enrichment strategy for potential registration."
• "We Believe LEVEL Confirms the Biological Thesis PRIMARY ENDPOINT MISSED ON PATIENT SELECTION, NOT ON DRUG EFFECT: LEVEL-2 IS DE-RISKED AS A RESULT THE BIOLOGY IS CONFIRMED THE MISS IS EXPLAINED LEVEL-2 IS DE-RISKED."
• "We Believe Learnings from LEVEL will De-risk LEVEL-2."
• "Strong treatment effect in patients with baseline 6MWD below the median (<333 M) is real: Prespecified subgroup finding supported by multivariable analysis."

Industry Context

StockSavvy.ai notes that the strategy of refining clinical trial enrollment based on post-hoc analysis of prior trial data is a common, albeit sometimes contentious, approach in drug development. The focus on a specific, more responsive patient subgroup for PH-HFpEF, a condition with significant unmet medical need and no approved treatments, reflects a targeted therapeutic development strategy. This approach aims to de-risk the trial by increasing the probability of demonstrating efficacy in a defined population.

Comparison to Industry Standards

• The LEVEL trial's primary endpoint miss, followed by an analysis identifying a responsive subgroup, is a pattern seen in other therapeutic areas. For instance, in pulmonary arterial hypertension (PAH), studies like SERAPHIN (macitentan), SUPER-1 (sildenafil), PHIRST (tadalafil), and TRIUMPH-1 (treprostinil) have shown stronger results in patients with lower baseline 6-minute walk distances (6MWD).
• Studies in PH-HFpEF, such as PRESERVED-HF (dapagliflozin), CADENCE (sotatercept), and HELP (IV levosimendan), have also reported positive outcomes, often with baseline 6MWD values in a similar range to the responsive subgroup identified in the LEVEL trial (e.g., PRESERVED-HF mean baseline 244 M, CADENCE median 259 M, HELP median 282 M).
• The company's proposed enrichment criteria for LEVEL-2 (e.g., baseline 6MWD <= 300m or 300m < 6MWD <= 400m with RAVI <= 25 mL/m2) align with industry trends of targeting sicker patients with greater potential for improvement.

Stakeholder Impact

• Shareholders: The strategic refinement of the LEVEL-2 trial and temporary pause in enrollment may introduce uncertainty regarding the timeline and ultimate success of the drug candidate, potentially impacting stock valuation.
• Patients: The amended trial design aims to enroll patients who are more likely to benefit from the treatment, potentially leading to more meaningful clinical outcomes for this specific subgroup.
• Healthcare Providers: The updated trial criteria will require careful patient selection, and the company's interpretation of the LEVEL data will influence treatment discussions and future prescribing patterns if approved.

Next Steps

• Amend the LEVEL-2 clinical trial protocol to incorporate enriched enrollment criteria.
• Resume enrollment in the LEVEL-2 trial at each site as the amended protocol goes into effect.
• Discuss the overall development of levosimendan with the FDA via a Type C meeting.
• Publish a protocol design paper for LEVEL-2 in Q1 2027.
• Provide further updates on levosimendan development in Q1 2027.

Key Dates

Recommendation

The company has demonstrated a clear path forward by identifying a responsive patient subgroup and is strategically adjusting its ongoing trial. However, the primary endpoint miss in the LEVEL trial and the temporary pause in enrollment introduce significant uncertainty. While the company's rationale for the pivot is sound, the success of the enriched LEVEL-2 trial is not guaranteed. Therefore, a 'hold' recommendation is appropriate, pending further data from the amended trial.

Keywords

PH-HFpEF, Levosimendan, TNX-103, Clinical Trial, Pulmonary Hypertension, Heart Failure, Enrollment, FDA